상세 보기
Safety and Efficacy of rhBMP-2 for Treating Acute Traumatic Fractures of the Upper and Lower Extremities: A Multicenter Prospective Study
- Sakong, Seungyeob;
- Hong, Seokjun;
- Choi, Wonseok;
- Kang, Seong Hyun;
- Cho, Jae Woo;
- ... Oh, Jong Keon;
- 외 4명
WEB OF SCIENCE
0SCOPUS
0초록
Background: Delayed or non-union fractures comprise 5-10% of cases, indicating the need for biologic interventions. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a potent osteoinductive agent; yet, collagen carrier-based uncontrolled release causes adverse events. We evaluated the safety and efficacy of a hydroxyapatite (HA) carrier-based rhBMP-2 delivery system for acute traumatic upper and lower fractures exhibiting bone defects. Methods: This prospective, multicenter, single-arm clinical trial enrolled 90 patients who underwent surgery using a hydroxyapatite (HA) carrier-based rhBMP-2 delivery system (NovosisTM). Radiographically validated union at 6 and 12 months post-surgery and treatment success (union without additional surgery) were used to assess efficacy. The incidence, type, and severity of all device-related adverse events during follow-up were monitored by investigators to evaluate safety. Results: Of the 90 patients enrolled, 81 were included in the full analysis set. The mean age was 58.5 years, and 18.6% (15/81) had open fractures. At 6 months post-surgery, radiographically validated union was achieved in 81.5% (66/81) of patients, increasing to 96.2% (77/81) at 12 months after surgery. Treatment success was 95.0% (76/81). Adverse events were rare (1/81, 1.2%). No ectopic ossification, systemic complications, or severe inflammatory responses were observed. Conclusions: HA-based rhBMP-2 intervention demonstrated favorable union rates and safety with minimal complications in acute upper and lower fractures with bone defects. The biocompatibility and controlled-release properties of HA likely improved efficacy and reduced complications. Results should be interpreted as feasibility data from a heterogeneous case series without a control group. Larger randomized controlled comparative trials are warranted for optimal dosing and evaluating efficacy and cost-effectiveness.
키워드
- 제목
- Safety and Efficacy of rhBMP-2 for Treating Acute Traumatic Fractures of the Upper and Lower Extremities: A Multicenter Prospective Study
- 저자
- Sakong, Seungyeob; Hong, Seokjun; Choi, Wonseok; Kang, Seong Hyun; Cho, Jae Woo; Son, Whee Sung; Choi, Jeong-Seok; Yon, Chang-Jin; Cho, Won-Tae; Oh, Jong Keon
- 발행일
- 2026-02
- 유형
- Article
- 저널명
- Journal of Clinical Medicine
- 권
- 15
- 호
- 3
- 언어
- ENG
- 출판사
- MDPI AG
- 발행국가
- 스위스
- ISSN
- E 2077-0383
P 2077-0383